Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2015

View Archived Issues

Novel conjugated vaccine shows greater protection against anthrax in mice

Hanmi initiates phase I trial of weekly-dosing formulation of basal insulin

Serendex to conduct phase II trial of inhaled GM-CSF in pneumonia-associated ARDS

VLPs show efficacy as pandemic avian influenza virus vaccines

BAY-94-9027 prophylaxis based on bleeding phenotype leads to greater control

New Bcl-2 inhibitors disclosed by Servier and Vernalis

Bayer divulges dual BRD4/PLK1 inhibitors

Actelion patents CXCR3 receptor antagonists

Janssen discloses new anti-HBV compounds

Polish and French team discloses 5-HT6 receptor antagonists

Actavis to divest Pharmatech to TPG

PEG-rFVIII shows safety and efficacy in hemophilia A patients

Small-sized Mucosolvan approved in Japan

Hospira launches first biosimilar MAb in major European markets

Galapagos reports promising phase I data for GLPG-1690

Dako and Ono Pharmaceutical to develop companion diagnostic test for Opdivo

Motesanib fails to achieve primary endpoint in phase III trial in NSCLC

FDA awards orphan drug designation to trofinetide for Rett syndrome

Molecular Templates recruits participants in phase I trial of MT-3724

Crown Bioscience acquires patient-derived xenograft models business from Molecular Response

CLS presents PK results of rFIX-albumin fusion protein

Great Basin begins clinical trial for Shiga toxin-producing E. coli diagnostic test

Hyperion Therapeutics enters into DiaPep277 agreements

FDA grants orphan drug status to RPC-4046 for eosinophilic esophagitis

Reolysin receives FDA orphan drug status for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...